Scientist Who Was Offline'Living His Best Life' Stunned by Nobel Prize Win Fred Ramsdell was on vacation in the Montana wilderness when he and two colleagues received the honor for their breakthroughs in immunology. When Fred Ramsdell, 64, was named a Nobel Prize winner earlier this week, he was deep in the Wyoming mountains, blissfully offline and surrounded by fresh snow. The next day, as he was wrapping up a three-week backpacking trip with his wife, her phone began to light up with hundreds of messages about the good news: Ramsdell, along with Mary E. Brunkow and Shimon Sakaguchi, had won the 2025 Nobel Prize in Physiology or Medicine for their discoveries that reshaped immunology . Ramsdell tells WIRED he was completely unaware that the Nobel Prizes were being announced, let alone that the Nobel committee was trying to get in touch with him. Sonoma Biotherapeutics, the biotechnology firm he co-founded, told reporters that Ramsdell was "was living his best life and was off the grid on a preplanned hiking trip."

This study investigates the relationship between tweet sentiment across diverse categories: news, company opinions, CEO opinions, competitor opinions, and stock market behavior in the biotechnology sector, with a focus on understanding the impact of social media discourse on investor sentiment and decision-making processes. We analyzed historical stock market data for ten of the largest and most influential pharmaceutical companies alongside Twitter data related to COVID-19, vaccines, the companies, and their respective CEOs. Using VADER sentiment analysis, we examined the sentiment scores of tweets and assessed their relationships with stock market performance. We employed ARIMA (AutoRegressive Integrated Moving Average) and VAR (Vector AutoRegression) models to forecast stock market performance, incorporating sentiment covariates to improve predictions. Our findings revealed a complex interplay between tweet sentiment, news, biotech companies, their CEOs, and stock market performance, emphasizing the importance of considering diverse factors when modeling and predicting stock prices. This study provides valuable insights into the influence of social media on the financial sector and lays a foundation for future research aimed at refining stock price prediction models.

Defense companies exploring artificial intelligence will help the U.S. military "keep up" with rivals like China, a former fighter pilot told Fox News. The Senate version of the National Defense Authorization Act could include a House-authored provision that prohibits the United States government and its contractors from buying equipment from "adversarial biotech companies" that work to "exploit" Americans' genetic information for "malign purposes," Fox News Digital has learned. Both the Senate and the House of Representatives are currently conferencing and negotiating on final NDAA text that can be passed by both chambers. The provision, which was passed in the original House bill, was introduced by House China Select Committee Chairman Mike Gallagher, R-Wis. The provision prohibits the purchase of biotechnology equipment or services from all United States adversaries, including North Korea, Russia, Iran and China.

Drug discovery companies such as Insilico Medicine are using deepfake AI technology to design new molecules that can help treat diseases. Intel made a splash earlier this week when it unveiled its latest technology that can detect a deepfake in real-time with 96pc accuracy. AI such as this can help organisations around the world to prevent the spread of misinformation and protect themselves from cybercrime. But not all kinds of deepfakes are bad. The advancement of any emerging technology brings with it positive and negative uses – and the future of healthcare certainly has much to gain from deepfakes.

Florian Ellsaesser Frankfurt School of Economics and Finance Guido Fioretti University of Bologna Gail E. James Gail James contributed a unique series of cognitive maps with her PhD thesis at University of Colorado, Boulder, 1996. We would like to have her as a co-author. If anyone knows where she is, please contact us. Abstract Sometimes unexpected, novel, unconceivable events enter our lives. The cause-effect mappings that usually guide our behaviour are destroyed. Surprised and shocked by possibilities that we had never imagined, we are unable to make any decision beyond mere routine. Among them there are decisions, such as making investments, that are essential for the long-term survival of businesses as well as the economy at large. We submit that the standard machinery of utility maximization does not apply, but we propose measures inspired by scenario planning and graph analysis, pointing to solutions being explored in machine learning. We wish to thank Jochen Runde and Jean Czerlinki for helpful comments and remarks on previous versions of this manuscript. Introduction Sometimes, unexpected events destroy certain causal relations that used to provide a few firm signposts in spite of all uncertainty involved in managing a business.

Artificial intelligence and other advanced analytical tools are increasingly popular with pharma firms and their research partners. Such technology can be useful for sorting through tall mountains of data to determine which candidates might offer hope to patients in need of a novel treatment for their particular condition. However, an AI-based approach might miss the mark by leaving out a human touch. David Harel, CEO and co-founder of Cytoreason, spoke with Outsourcing-Pharma about what tasks AI is best suited for, where it might fall short, and how to refine your approach toward drug discovery. OSP: Looking back on news OSP has shared about CytoReason, you've had an interesting few months.

Currently, it takes a staggering 10-15 years and costs $2.6 billion to develop a new drug, and an astonishing proportion of this is lost in the 90% of candidates that fail. AstraZeneca (AZ) is one of the world's largest Pharmaceutical companies and is incorporating AI in every step of the R&D chain from drug discovery to launch to make this process safer, quicker and less costly. The first step is learning more about diseases. AZ is using knowledge graphs (networks of vast scientific data and the relationship between these) to gather new insights about diseases which would allow for more focused research. In order to learn more about pathology, we must gain a firm understanding of human genomes.

Naheed Kurji is the President and CEO of Cyclica, a Toronto-based biotechnology company that leverages artificial intelligence and computational biophysics to reshape the drug discovery process. Cyclica leverages artificial intelligence and computational biophysics to reshape the drug discovery process. Can you discuss in what way AI is used in this process? Technology has played a critical role in drug discovery dating back to the '80s. However, the drug discovery and development process is still very inefficient, time consuming and expensive, costing more than 2 billion dollars over 12 years.

In 2011, scientists made one of the most important discoveries in the history of AI development. They found that graphics processing units (GPUs) are far better at simulating biological learning than central processing units (CPUs). In retrospect, it seems obvious. Human brains are much more like GPUs than CPUs. Both brains and GPUs rely on parallel processing that simulates and predicts real world physics.

The European Investment Bank today (November 29th) agreed a EUR 30 million facility to support investment by Dublin based biotech company, Nuritas, to further increase and accelerate development of artificial intelligence and DNA analysis to improve global healthcare. Representing the first direct EIB financing for an Irish biotech company, the new support will allow the company to access tranched financing as required to scale up the development of the rapidly growing company. Future investment by the company backed by the EIB will scale up development of new therapeutics in areas of interest including anti-aging, anti-inflammatory and diabetes treatment. "Nuritas has already demonstrated through PeptAIde, their first product launch this year, how the discovery of healthcare products can be rapidly accelerated using artificial intelligence. During due diligence over recent months the EIB has been impressed by their innovative use of technology and the number of global deals already achieved and they now become the first Irish biotech firm to benefit from the EIB's dedicated European Growth Finance Facility. Our goal is to find innovative and fast-growing companies so that we ensure they can benefit from access to long-term financing under the new initiative and Nuritas fits this bill perfectly. We look forward to working with other innovative and fast growing companies to ensure they can benefit from access to long-term financing under the new initiative. This new EUR 30 million support from the European Investment Bank will enable Nuritas to expand and commercialise even faster." said Andrew McDowell, European Investment Bank Vice President.